Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Chinese Patent Office
Citi
Mallinckrodt
Boehringer Ingelheim
Merck
Teva
Healthtrust
US Department of Justice

Generated: May 23, 2018

DrugPatentWatch Database Preview

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Vaprisol In 5% Dextrose In Plastic Container patents expire, and when can generic versions of Vaprisol In 5% Dextrose In Plastic Container launch?

Vaprisol In 5% Dextrose In Plastic Container is a drug marketed by Cumberland Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-nine patent family members in seventeen countries.

The generic ingredient in VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER is conivaptan hydrochloride. One supplier is listed for this compound. Additional details are available on the conivaptan hydrochloride profile page.
Summary for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Drug patent expirations by year for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Pharmacology for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

US Patents and Regulatory Information for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland Pharms VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER conivaptan hydrochloride INJECTABLE;IV (INFUSION) 021697-002 Oct 8, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,856,564 Condensed benzazepine derivative and pharmaceutical composition thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Covington
Cantor Fitzgerald
Chubb
AstraZeneca
Moodys
Daiichi Sankyo
US Department of Justice
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.